VERTEX PHARMACEUTICALS INC / MA Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2017-02-23.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2012-12-31 was $874.00K.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2012-09-30 was -$117.00K.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2012-06-30 was $987.00K.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2012-03-31 was $227.00K.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was $2.16M.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2013 was -$1.25M, a 163.52% decline from fiscal 2012.
- VERTEX PHARMACEUTICALS INC / MA adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2012 was $1.97M, a 119.00% increase from fiscal 2011.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2017-02-23 | |||
| 2014-12-31 | $2.16M 10-K · filed 2017-02-23 | |||
| 2013-12-31 | -$1.25M 10-K · filed 2016-02-16 | |||
| 2012-12-31 | $874.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $757.00K derived: sum of 2 quarters · filed 2015-02-13 | $1.74M derived: sum of 3 quarters · filed 2015-02-13 | $1.97M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $870.00K derived: sum of 2 quarters · filed 2013-11-07 | $1.10M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $987.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $1.21M 10-Q · filed 2013-08-02 | ||
| 2012-03-31 | $227.00K 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | $900.00K 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |